These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27482887)

  • 1. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 inhibitor FX1 attenuates inflammatory responses in murine sepsis through strengthening BCL6 binding affinity to downstream target gene promoters.
    Zhang H; Qi X; Wu J; Huang X; Zhang A; Chen S; Ding X; Chen S; Le S; Zou Y; Xu H; Ye P; Xia J
    Int Immunopharmacol; 2019 Oct; 75():105789. PubMed ID: 31401377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
    Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
    Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
    Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
    Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of BCL6 in lymphomas and routes to therapy.
    Wagner SD; Ahearne M; Ko Ferrigno P
    Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
    Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
    Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
    McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
    ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
    Guo W; Xing Y; Zhang Q; Xie J; Huang D; Gu H; He P; Zhou M; Xu S; Pang X; Liu M; Yi Z; Chen Y
    J Med Chem; 2020 Jan; 63(2):676-695. PubMed ID: 31895575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.
    Mi D; Li C; Li Y; Yao M; Li Y; Hong K; Xie C; Chen Y
    Eur J Med Chem; 2024 Nov; 277():116789. PubMed ID: 39208743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
    Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
    Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
    J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.